TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells.

Two products from the adipose-derived stem cell technology platform are currently in clinical development.

- Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients. On July 4, 2016, we entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States.

- Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. 

Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI).

In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication.

TiGenix is based in Leuven, Belgium, and has operations in Madrid, Spain.




Latest News

17 October 2016 - TiGenix Announces Orphan Drug Designation (ODD) for Cx601 in Switzerland (EN - NL - FR)

22 September 2016 - TiGenix Appoints Dr. June Almenoff to its Board of Directors (EN - NL - FR)

20 September 2016 - TiGenix Business and Financial Update for the First Half 2016 (EN - NL - FR)

2 August 2016 - Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease (EN - NL - FR)

20 July 2016 - Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix (EN - NL)


Company slide deck

2016 - Corporate Presentation

Management presentations

First Half 2016 Business and Financial Update

ECCO Plenary ADMIRE-CD presentation

TiGenix ECCO Symposium presentations

Interview with De Tijd, 23 September 2015

Mediafin Investor Night (ENG - FR), 23 September 2015

HY15 results webcast presentation 15 September 2015

1H 2015 results webcast recording, September 2015

TiGenix Cx601 ADMIRE-CD Top-Line Results Webcast, August 2015

Tigenix at Alliance for Regenerative Medicine Conference, March 2015

TiGenix on Kanaal Z television, November 2014